Eli Lilly and Company (LLY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eli Lilly and Company (LLY) has a cash flow conversion efficiency ratio of 0.316x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.69 Billion) by net assets ($33.88 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LLY market cap overview for the company's overall valuation and market capitalisation.
Eli Lilly and Company - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Eli Lilly and Company's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eli Lilly and Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eli Lilly and Company ranked by their cash flow conversion efficiency. Explore Eli Lilly and Company (LLY) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Walmart Inc
SA:WALM34
|
0.286x |
|
Space Exploration Technologies Corp. Class A Common Stock
NASDAQ:SPCX
|
0.019x |
|
SK Hynix Inc. American Depositary Shares
NASDAQ:SKHY
|
0.249x |
|
Tesla Inc
NASDAQ:TSLA
|
0.054x |
|
Samsung Electronics Co Ltd
KO:005930
|
0.055x |
|
JPMorgan Chase & Co
NYSE:JPM
|
-0.067x |
|
Walmart Inc. Common Stock
NYSE:WMT
|
0.095x |
|
Eli Lilly and Company
SA:LILY34
|
0.171x |
Annual Cash Flow Conversion Efficiency for Eli Lilly and Company (1989–2025)
The table below shows the annual cash flow conversion efficiency of Eli Lilly and Company from 1989 to 2025. View Eli Lilly and Company stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.54 Billion | $16.81 Billion | 0.634x | +2.55% |
| 2024-12-31 | $14.27 Billion | $8.82 Billion | 0.618x | +58.30% |
| 2023-12-31 | $10.86 Billion | $4.24 Billion | 0.390x | -40.64% |
| 2022-12-31 | $10.78 Billion | $7.08 Billion | 0.657x | -17.10% |
| 2021-12-31 | $9.15 Billion | $7.26 Billion | 0.793x | -28.92% |
| 2020-12-31 | $5.83 Billion | $6.50 Billion | 1.116x | -37.73% |
| 2019-12-31 | $2.70 Billion | $4.84 Billion | 1.792x | +253.85% |
| 2018-12-31 | $10.91 Billion | $5.52 Billion | 0.506x | +5.22% |
| 2017-12-31 | $11.67 Billion | $5.62 Billion | 0.481x | +39.70% |
| 2016-12-31 | $14.08 Billion | $4.85 Billion | 0.345x | +69.56% |
| 2015-12-31 | $14.59 Billion | $2.96 Billion | 0.203x | -29.87% |
| 2014-12-31 | $15.39 Billion | $4.46 Billion | 0.290x | -10.88% |
| 2013-12-31 | $17.64 Billion | $5.74 Billion | 0.325x | -9.46% |
| 2012-12-31 | $14.77 Billion | $5.30 Billion | 0.359x | -32.82% |
| 2011-12-31 | $13.54 Billion | $7.23 Billion | 0.534x | -3.24% |
| 2010-12-31 | $12.41 Billion | $6.86 Billion | 0.552x | +21.36% |
| 2009-12-31 | $9.53 Billion | $4.34 Billion | 0.455x | -57.98% |
| 2008-12-31 | $6.74 Billion | $7.30 Billion | 1.083x | +181.95% |
| 2007-12-31 | $13.42 Billion | $5.15 Billion | 0.384x | +6.10% |
| 2006-12-31 | $10.98 Billion | $3.98 Billion | 0.362x | +104.20% |
| 2005-12-31 | $10.79 Billion | $1.91 Billion | 0.177x | -32.52% |
| 2004-12-31 | $10.92 Billion | $2.87 Billion | 0.263x | -29.64% |
| 2003-12-31 | $9.76 Billion | $3.65 Billion | 0.373x | +49.22% |
| 2002-12-31 | $8.27 Billion | $2.07 Billion | 0.250x | -51.44% |
| 2001-12-31 | $7.10 Billion | $3.66 Billion | 0.515x | -16.47% |
| 2000-12-31 | $6.05 Billion | $3.73 Billion | 0.617x | +18.09% |
| 1999-12-31 | $5.01 Billion | $2.62 Billion | 0.523x | -11.98% |
| 1998-12-31 | $4.43 Billion | $2.63 Billion | 0.594x | +18.86% |
| 1997-12-31 | $4.81 Billion | $2.40 Billion | 0.500x | +53.01% |
| 1996-12-31 | $6.10 Billion | $1.99 Billion | 0.326x | -2.80% |
| 1995-12-31 | $5.43 Billion | $1.82 Billion | 0.336x | +17.39% |
| 1994-12-31 | $5.36 Billion | $1.53 Billion | 0.286x | -13.83% |
| 1993-12-31 | $4.57 Billion | $1.52 Billion | 0.332x | +9.49% |
| 1992-12-31 | $4.89 Billion | $1.48 Billion | 0.303x | +20.03% |
| 1991-12-31 | $4.97 Billion | $1.25 Billion | 0.253x | -40.59% |
| 1990-12-31 | $3.47 Billion | $1.47 Billion | 0.425x | +54.71% |
| 1989-12-31 | $3.76 Billion | $1.03 Billion | 0.275x | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more